NeuroMab™ Anti-TLR2 BBB Shuttle Antibody(NRZP-1022-ZP2657)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human; Cynomolgus Monkey; Mouse

Clonality

Monoclonal

Host Species

Mouse

Applications

ELISA; Block; Inhib; In Vitro; In Vivo

Relevant Diseases

Alzheimer's Disease; Parkinson's Disease; Ischemic Stroke; Multiple Sclerosis; Neuroinflammation

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

CD282

Official Name

TLR2

Full Name

Toll-like receptor 2

Alternative Names

TLR2

Product Pictures

ELISA

Fig.1 is a bar graph depicting the results of enzyme linked immunosorbant assays (ELISAs) of the level of IL-6 expression in the presence or absence of TLR1 mAb (GD2.F4) or TLR2 mAb (11G7) in human PMBCs in the presence or absence of araLAM or PaM3CSK4.

Lysates of 1×106 murine RAW264.7 macrophages or HEK293 cells, 1 μg of each antibody as indicated, and 20 μl of protein G beads (Santa Cruz, Calif., USA) were mixed for o. n. precipitation. Immune complexes were analyzed by immunoblot analysis with either Flag- or murine TLR2-specific antiserum.

ELISA

Fig.2 is a graph depicting the results of experiments in which the level of IL-8 expression (pg/ml) was assayed in the presence of varying concentrations of control antibody (OKT8), anti-CD14 (26ic), anti-TLR1 (GD2.F4), anti-TLR2 (TL2. 1), and both anti-TLR1 and anti-TLR2.

ELISA

Fig.3 is a bar graph depicting the results of ELISAs assaying the level of IL-6 expression in human PMBCs in the presence or absence of TLR1 mAb (GD2.F4) or TLR2 mAb (11G7), and in the presence or absence of zymosan or pLPS.

ELISA

Fig.4 is a graph depicting the results of experiments in which the level of IL-8 expression was assayed in the presence of anti-TLR1 (GD2.F4), anti-TLR2 (TL2.1), and control IgG or anti-TLR1, anti-TLR2, and anti-CD14 monoclonal antibodies. TLR1 and TLR2 antibodies were provided at 0.2 μg/ml. Varying concentrations of isotype control or anti-CD14 antibodies were used.

Publications